TorreyPines said under the agreement, which began in February 2005, Eisai has exclusive rights of first negotiation and refusal for validated compounds that are discovered through the research. TorreyPines and Eisai may enter into development agreements involving the validated compounds.
“We are excited about extending this agreement with Eisai, a leader in Alzheimer's disease research and treatment,” said Neil Kurtz, managing director, president and CEO of TorreyPines.
“We look forward to advancing the small molecule program further with Eisai's support, as well as to continuing to work with them on our initial research collaboration to identify genetically-validated pharmaceutical targets for Alzheimer's disease,” Mr Kurtz added.